Results 61 to 70 of about 15,072 (244)

Risk factors for the development of subretinal fluid in the fellow eyes of patients with chronic central serous chorioretinopathy

Acta Ophthalmologica, EarlyView.
Abstract Purpose To assess the risk of subretinal fluid (SRF) development in the fellow eye of chronic central serous chorioretinopathy (cCSC) patients with unilateral SRF at baseline. Methods Medical records of 334 presumed cCSC patients were retrospectively reviewed.
Helena M. A. Feenstra, Tahir Cakar, Joost Brinks, Camiel J. F. Boon, Elon H. C. van Dijk   +4 more
wiley   +1 more source

Intramyocardial gene silencing by interfering RNA [PDF]

, 2017
RNAi is a widely used methodology for gene silencing. The action mechanism of siRNA molecules has been well studiedin recent years, and the technique has been optimized in terms of safety and effectiveness. Cardiovascular diseases havea high incidence in
Brea, María Soledad, Morgan, Patricio Eduardo, Perez, Nestor Gustavo   +2 more
core   +1 more source

Comparative effectiveness and safety of eplerenone and spironolactone in patients with heart failure: a systematic review and meta-analysis

BMC Cardiovascular Disorders
Background Eplerenone and spironolactone, recognized as mineralocorticoid receptor antagonists (MRAs), have been reported to improve clinical prognosis among individuals diagnosed with heart failure (HF).
Ahmed Elshahat, Ahmed Mansour, Mohamed Ellabban, Ahmed Diaa, Atef Hassan, Ahmed Fawzy, Omar Abdulrahman Saad, Moaz Abouelmagd, Mahmoud Eid, Ahmed Elaraby, Mohamed Hamouda Elkasaby, Ahmed Abdelaziz   +11 more
doaj   +1 more source

Efficacy and Safety of Eplerenone for Treating Chronic Kidney Disease: A Meta-Analysis

International Journal of Hypertension, 2023
Background. In recent years, a large amount of clinical evidence and animal experiments have demonstrated the unique advantages of mineralocorticoid receptor antagonists (MRA) for treating chronic kidney disease (CKD). Aims.
Honglei Hu, Mengdie Cao, Yao Sun, Xingqian Jin, Xiaodong Zhao, Xiangguo Cong   +5 more
doaj   +1 more source

Long‐term follow‐up of chronic central serous chorioretinopathy patients receiving oral eplerenone and half‐dose photodynamic therapy in the SPECTRA trial: SPECTRA trial report No. 4

Acta Ophthalmologica, EarlyView.
Abstract Purpose Assessing the 24‐month treatment outcome of half‐dose photodynamic therapy (PDT) or oral eplerenone in chronic central serous chorioretinopathy (cCSC). Methods Multicentre randomized clinical trial included cCSC patients from the SPECTRA trial who were randomized to receive half‐dose PDT or oral eplerenone.
Helena M. A. Feenstra, Issam El Mansori, Thomas J. van Rijssen, Roula Tsonaka, Roselie M. H. Diederen, Carel B. Hoyng, Reinier O. Schlingemann, Camiel J. F. Boon, Elon H. C. van Dijk   +8 more
wiley   +1 more source

Mineralocorticoid receptor antagonists: Efficacy and safety in chronic kidney disease

Diabetes, Obesity and Metabolism, EarlyView.
Abstract The mineralocorticoid receptor (MR) has a multifaceted role in normal physiologic functions. However, research has uncovered the deleterious consequences of overactivation of the MR. It has been implicated in chronic kidney disease (CKD) via its strong association with glomerulosclerosis, interstitial fibrosis, proteinuria, and decline in ...
Amy K. Mottl, Kamlesh Khunti, Chantal Mathieu   +2 more
wiley   +1 more source

Risk of Acute Kidney Injury Associated With Nephrotoxic Burden in Hospitalized Patients: A Scoping Review

Clinical Pharmacology &Therapeutics, Volume 119, Issue 4, Page 891-904, April 2026.
Limited evidence exists synthesizing the risk of acute kidney injury (AKI) associated with the concomitant administration of multiple nephrotoxic drugs, and even less examining the concept of nephrotoxic burden. The objective of this scoping review was to (1) identify definitions of nephrotoxic burden; (2) methods used to quantify (use of calculations)
Wafa Alatawi, Jessica L. Wallace, Dhakrit Rungkitwattanakul, Britney A. Stottlemyer, Tiffany L. Tran, Melanie Manis Reida, Sandra L. Kane‐Gill   +6 more
wiley   +1 more source

The Multi-Biomarker Approach for Heart Failure in Patients with Hypertension [PDF]

, 2015
We assessed the predictive ability of selected biomarkers using N-terminal pro-brain natriuretic peptide (NT-proBNP) as the benchmark and tried to establish a multi-biomarker approach to heart failure (HF) in hypertensive patients. In 120 hypertensive
Agata Bielecka-Dabrowa, Anna Gluba-Brzózka, Campeau, Jacek Rysz, Li, Maciej Banach, Marta Michalska-Kasiczak, Małgorzata Misztal, McCullough, Ravassa, Wei   +10 more
core   +2 more sources

Analysis of eplerenone in the FDA adverse event reporting system (FAERS) database: a focus on overall patient population and gender-specific subgroups

Frontiers in Pharmacology
Introduction: Eplerenone is approved for the treatment of hypertension as well as symptomatic heart failure with reduced ejection fraction (HFrEF) following an acute myocardial infarction.
Xin Guan, Yusi Yang, Xinru Li, Yue Feng, Jizhen Li, Xuewen Li   +5 more
doaj   +1 more source

Eplerenone attenuates pulse wave reflection in chronic kidney disease stage 3-4--a randomized controlled study. [PDF]

PLoS ONE, 2013
Patients with chronic kidney disease (CKD) have high cardiovascular mortality and morbidity associated with increased arterial stiffness. Plasma aldosterone levels are increased in CKD, and aldosterone has been found to increase vascular inflammation and
Lene Boesby, Thomas Elung-Jensen, Svend Strandgaard, Anne-Lise Kamper   +3 more
doaj   +1 more source